Yuncong Technology: "The R&D team of large-scale model agent products is basically dissolved" is all false information. Yuncong Technology said on the interactive platform that the company's R&D team is stable at present, and a rigorous and meticulous hierarchical division of labor system has been established for the research and development of large-scale model related products. The configuration of R&D echelon will be flexibly adjusted according to the continuous evolution of large model technology and the changes of market demand of agent products. The statements of "the No.1 position of the big model algorithm" and "the R&D team of the big model agent product is basically dissolved" mentioned in the question are false information, and the company reserves the right to pursue legal responsibility for this. The company has been unswervingly promoting the research and product development of large-scale model and agent-related technologies.Australian Government: Australia will provide Papua New Guinea with $600 million in 10 years to help rugby league teams enter Australia's top leagues.The tenth batch of national procurement officially opened, and the number of enterprises and varieties involved reached a record high. The tenth batch of centralized drug procurement organized by the state officially accepted the application materials of enterprises at 8: 00 this morning at No.398 Zhanyuan Road, Nanqiao New Town, Fengxian District, Shanghai. This centralized procurement involved 62 varieties and 263 product specifications, and the number of enterprises and varieties involved reached a record high. Among them, 33 enterprises competed for nine short-listed oral sustained-release formulations of sitagliptin. There are also a number of varieties that are billions in the market of public hospitals, such as doxorubicin hydrochloride liposome injection, cefoperazone injection, piperacillin injection, compound α -ketoacid oral sustained-release dosage form, norepinephrine injection and aspirin oral sustained-release dosage form. The sales scale in sample hospitals last year all exceeded 2 billion yuan. Hengrui Pharma, Kelun Pharmaceutical, Unacon and Zhengda Tianqing participated with many varieties. Note: According to the tenth batch of national adoption documents released before, the tenth batch of national adoption rules have changed a lot, such as canceling the protection mechanism of 50% price reduction and increasing the fuse recovery mechanism by 1.8 times, and the number of B-certified enterprises affects the number of final finalists.
Japan's net foreign investment in Japanese stocks in the week of December 6 was 482.3 billion yen, with the previous value of-607.7 billion yen. Japan's net foreign investment in Japanese bonds in the week of December 6 was 1,006.4 billion yen, with the previous value of 176.1 billion yen. Japan bought a net foreign bond of-640.8 billion yen in the week of December 6, with the previous value of 922.4 billion yen. In the week of December 6th, Japan bought foreign stocks net-954.8 billion yen, with the previous value of-544.7 billion yen.CICC: Inflation in the United States may push the "hawks to cut interest rates". The CICC research report said that inflation data opened the door for the Fed to cut interest rates next week, but we also predicted that the "hawks to cut interest rates" will be staged next week, and the Fed may cut the guidance on interest rate cuts in the bitmap. We predict that the new bitmap will show that the total interest rate will be cut twice in 2025 (compared with four times before), and the federal funds rate will be lowered to a neutral level of 3.75% to 4% by the end of the second quarter of next year.The yield of 10-year Japanese government bonds rose by 1 basis point to 1.075%.
Australia's ASX 200 index narrowed to 0.1%, and the Australian dollar increased. The just released Australian employment data was better than expected.South Korean President Yin Xiyue: The opposition party does not recognize the president.Huatai Securities: It is expected that the Fed will cut interest rates by 25bp in December, but the path of interest rate cut in 2025 is highly uncertain. Huatai Securities said that the overall inflation in November in the United States was in line with expectations, and the slight cooling of service inflation partially eased the market's concerns about inflation rebound. It is expected that the Fed will cut interest rates by 25bp in December, but the path of interest rate cut in 2025 is highly uncertain. Recently, the overall economic momentum of the United States has rebounded: from September to November, the PMI of Markit manufacturing in the United States has rebounded for three consecutive months; After the election, enterprises, especially small enterprises, are expected to improve, and the recent NFIB SME confidence index has rebounded significantly; The latest Atlanta GDP Now shows that the fourth quarter GDP growth rate of the United States is 3.3% year-on-year. However, considering that the unemployment rate data rebounded in November, and the recent inflation is still relatively moderate, we expect that the recent data may not prevent the Fed from cutting interest rates at its December meeting next week. However, in 2025, the growth and inflation path of the United States was disturbed by the Trump policy, and the Federal Reserve may "make a camera choice" on the basis of watching the overall economic trend. There is uncertainty in the path of interest rate cut in 2025.
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
Strategy guide